The Effect of Dapagliflozin on Renal Disease Progression
Nov 28, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Abdullah Al-Ajmi, PharmD Candidate, Skaggs School of Pharmacy and Pharmaceutical Sciences
Chronic kidney disease (CKD) affects around 700million people worldwide and is linked to a decreased quality of life and increased mortality rates. To date, only angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are proven to have renal protective outcomes in patients with type 2 diabetes mellitus (T2DM). Favorable effects were also reported with sodium-glucose cotransporter 2 (SGLT2) inhibitors in cardiovascular and renal outcomes. In the CREDENCE trial, the results showed that long term use of canagliflozin provides cardiovascular and renal protection in patients with T2DM. The exact mechanism is not well known, but it is suggested that the overall effect of SGLT2-inhibitors on sodium and glucose excretion may reduce intraglomerular pressure, leading to renal preservation in patients with CKD.
This study aimed to assess the long-term effect of dapagliflozin in patients with CKD, regardless of whether they have T2DM or not....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.